Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 102 plus mitoxantrone and prednisone in previously treated castration-resistant prostate cancer
NL-OMON33942Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing AMG 102 + mitoxantrone + prednisone with Placebo + mitoxantrone + prednisone (2 arms). Primary endpoint: Overall survival. Started Jun 2009; status: active, not recruiting.
02
Drugs
rilotumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON33942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33942.